“…The following information was collected from medical records: age, gender, ethnicity, presence or absence of obesity (calculated by body mass index (BMI)), smoking, alcohol abuse (>30 g/day), sedentarism, accumulative dose of anthracyclines (>300 mg/m 2 ), previous use of anthracyclines, mediastinal irradiation, presence of previous cardiovascular diseases such as SAH, coronary heart disease, diabetes mellitus, dyslipidemia, tumor characteristics, hormone receptor status (progesterone and estrogen), presence of HER-2 receptor overexpression, signs and symptoms suggestive of HF and cardiotoxicity to the use of rituximab and trastuzumab, prior chemotherapy concomitant with antibodies, ECHO and LVEF results. A cardiotoxicity assessment form, described by Valente et al, 16 was completed for all patients enrolled in the study. All patients underwent an initial ECHO.…”